Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s67. https://doi.org/10.25251/skin.6.supp.67